Search

Your search keyword '"Nerla, Roberto"' showing total 300 results
Start Over Author "Nerla, Roberto"
300 results on '"Nerla, Roberto"'

1. A Prospective Randomized Trial Comparing Sirolimus-Coated Balloon With Paclitaxel-Coated Balloon in De Novo Small Vessels

Author

Ninomiya, Kai, Serruys, Patrick W., Colombo, Antonio, Reimers, Bernhard, Basavarajaiah, Sandeep, Sharif, Faisal, Testa, Luca, Di Mario, Carlo, Nerla, Roberto, Ding, Daixin, Huang, Jiayue, Kotoku, Nozomi, Kageyama, Shigetaka, Kageyama, Momoko, Sevestre, Emelyne, Fezzi, Simone, Dijkstra, Jouke, O’Leary, Neil, Morel, Marie Angele, Garg, Scot, Cortese, Bernardo, and Onuma, Yoshinobu

Published
2023
Full Text
View/download PDF

2. Transcatheter aortic valve replacement with the self-expanding ACURATE Neo2 in patients with horizontal aorta: Insights from the ITAL-neo registry

Author

Barki, Monica, Ielasi, Alfonso, Buono, Andrea, Maffeo, Diego, Montonati, Carolina, Pellegrini, Dario, Pellicano, Mariano, Gorla, Riccardo, Costa, Giuliano, Cozzi, Ottavia, Ancona, Marco, Soriano, Francesco, De Carlo, Marco, Ferrara, Erica, Giannini, Francesco, Massussi, Mauro, Fovino, Luca Nai, Messina, Antonio, Sgroi, Carmelo, Gallo, Francesco, Nerla, Roberto, Saccocci, Matteo, D'Ascenzo, Fabrizio, Conrotto, Federico, Bettari, Luca, Fiorina, Claudia, Castriota, Fausto, Poli, Arnaldo, Petronio, Anna Sonia, Oreglia, Jacopo, Montorfano, Matteo, Regazzoli, Damiano, Reimers, Bernhard, Barbanti, Marco, Tamburino, Corrado, Bedogni, Francesco, Tarantini, Giuseppe, and Tespili, Maurizio

Published
2023
Full Text
View/download PDF

3. Vascular Access in Patients With Peripheral Arterial Disease Undergoing TAVR: The Hostile Registry

Author

Palmerini, Tullio, Saia, Francesco, Kim, Won-Keun, Renker, Matthias, Iadanza, Alessandro, Fineschi, Massimo, Bruno, Antonio Giulio, Ghetti, Gabriele, Vanhaverbeke, Maarten, Søndergaard, Lars, De Backer, Ole, Romagnoli, Enrico, Burzotta, Francesco, Trani, Carlo, Adrichem, Rik, Van Mieghem, Nicolas M., Nardi, Elena, Chietera, Francesco, Orzalkiewicz, Mateusz, Tomii, Daijiro, Pilgrim, Thomas, Aranzulla, Tiziana Claudia, Musumeci, Giuseppe, Adam, Matti, Meertens, Max M., Taglieri, Nevio, Marrozzini, Cinzia, Alvarez Covarrubias, Hector Alfonso, Joner, Michael, Nardi, Giulia, Di Muro, Francesca Maria, Di Mario, Carlo, Loretz, Lucca, Toggweiler, Stefan, Gallitto, Enrico, Gargiulo, Mauro, Testa, Luca, Bedogni, Francesco, Berti, Sergio, Ancona, Marco B., Montorfano, Matteo, Leone, Alessandro, Savini, Carlo, Pacini, Davide, Gmeiner, Jonas, Braun, Daniel, Nerla, Roberto, Castriota, Fausto, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Costa, Giuliano, Tamburino, Corrado, Leone, Pier Pasquale, Reimers, Bernhard, Stefanini, Giulio, Sudo, Mitsumasa, Nickenig, Georg, Piva, Tommaso, Scotti, Andrea, Latib, Azeem, Vercellino, Matteo, Porto, Italo, Codner, Pablo, Kornowski, Ran, Bartorelli, Antonio L., Tarantini, Giuseppe, Fraccaro, Chiara, Abdel-Wahab, Mohamed, Grube, Eberhard, Galié, Nazzareno, and Stone, Gregg W.

Published
2023
Full Text
View/download PDF

5. Comparison of two self-expanding transcatheter heart valves for degenerated surgical bioprostheses: the AVENGER multicentre registry

Author

Kim, Won-Keun, primary, Seiffert, Moritz, additional, Rück, Andreas, additional, Leistner, David M., additional, Dreger, Henryk, additional, Wienemann, Hendrik, additional, Adam, Matti, additional, Möllmann, Helge, additional, Blumenstein, Johannes, additional, Eckel, Clemens, additional, Buono, Andrea, additional, Maffeo, Diego, additional, Messina, Antonio, additional, Holzamer, Andreas, additional, Sossalla, Samuel, additional, Costa, Giuliano, additional, Barbanti, Marco, additional, Motta, Silvia, additional, Tamburino, Corrado, additional, von der Heide, Ina, additional, Glasmacher, Julius, additional, Sherif, Mohammad, additional, Seppelt, Philipp, additional, Fischtlscherer, Stephan, additional, Walther, Thomas, additional, Castriota, Fausto, additional, Nerla, Roberto, additional, Frerker, Christian, additional, Schmidt, Tobias, additional, Wolf, Alexander, additional, Adamaszek, Martin M., additional, Giannini, Francesco, additional, Vanhaverbeke, Maarten, additional, Van de Walle, Stefaan, additional, Stammen, Francis, additional, Toggweiler, Stefan, additional, Brunner, Stephanie, additional, Mangieri, Antonio, additional, Gitto, Mauro, additional, Kaleschke, Gerrit, additional, Ninios, Vlasis, additional, Ninios, Ilias, additional, Hübner, Judith, additional, Xhepa, Erion, additional, Renker, Matthias, additional, Charitos, Efstratios I., additional, Joner, Michael, additional, and Rheude, Tobias, additional

Published
2024
Full Text
View/download PDF

7. Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement: VIVID Registry

Author

Alperi, Alberto, Rodés-Cabau, Josep, Simonato, Matheus, Tchetche, Didier, Charbonnier, Gaetan, Ribeiro, Henrique B., Latib, Azeem, Montorfano, Matteo, Barbanti, Marco, Bleiziffer, Sabine, Redfors, Björn, Abdel-Wahab, Mohamed, Allali, Abdelhakim, Bruschi, Giuseppe, Napodano, Massimo, Agrifoglio, Marco, Petronio, Anna Sonia, Giannini, Cristina, Chan, Albert, Kornowski, Ran, Pravda, Nili Schamroth, Adam, Matti, Iadanza, Alessandro, Noble, Stephane, Chatfield, Andrew, Erlebach, Magdalena, Kempfert, Jörg, Ubben, Timm, Wijeysundera, Harindra, Seiffert, Moritz, Pilgrim, Thomas, Kim, Won-Keun, Testa, Luca, Hildick-Smith, David, Nerla, Roberto, Fiorina, Claudia, Brinkmann, Christina, Conzelmann, Lars, Champagnac, Didier, Saia, Francesco, Nissen, Henrik, Amrane, Hafid, Whisenant, Brian, Shamekhi, Jasmin, Søndergaard, Lars, Webb, John G., and Dvir, Danny

Published
2021
Full Text
View/download PDF

8. Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve Bioprostheses

Author

Landes, Uri, Sathananthan, Janarthanan, Witberg, Guy, De Backer, Ole, Sondergaard, Lars, Abdel-Wahab, Mohamed, Holzhey, David, Kim, Won-Keun, Hamm, Christian, Buzzatti, Nicola, Montorfano, Matteo, Ludwig, Sebastian, Conradi, Lenard, Seiffert, Moritz, Guerrero, Mayra, El Sabbagh, Abdallah, Rodés-Cabau, Josep, Guimaraes, Leonardo, Codner, Pablo, Okuno, Taishi, Pilgrim, Thomas, Fiorina, Claudia, Colombo, Antonio, Mangieri, Antonio, Eltchaninoff, Helene, Nombela-Franco, Luis, Van Wiechen, Maarten P.H., Van Mieghem, Nicolas M., Tchétché, Didier, Schoels, Wolfgang H., Kullmer, Matthias, Tamburino, Corrado, Sinning, Jan-Malte, Al-Kassou, Baravan, Perlman, Gidon Y., Danenberg, Haim, Ielasi, Alfonso, Fraccaro, Chiara, Tarantini, Giuseppe, De Marco, Federico, Redwood, Simon R., Lisko, John C., Babaliaros, Vasilis C., Laine, Mika, Nerla, Roberto, Castriota, Fausto, Finkelstein, Ariel, Loewenstein, Itamar, Eitan, Amnon, Jaffe, Ronen, Ruile, Philipp, Neumann, Franz J., Piazza, Nicolo, Alosaimi, Hind, Sievert, Horst, Sievert, Kolja, Russo, Marco, Andreas, Martin, Bunc, Matjaz, Latib, Azeem, Godfrey, Rebecca, Hildick-Smith, David, Chuang, Ming-Yu A., Blanke, Philipp, Leipsic, Jonathon, Wood, David A., Nazif, Tamim M., Kodali, Susheel, Barbanti, Marco, Kornowski, Ran, Leon, Martin B., and Webb, John G.

Published
2021
Full Text
View/download PDF

12. Impact of Ethnicity on Antiplatelet Treatment Regimens for Bleeding Reduction in Acute Coronary Syndromes: A Systematic Review and Pre-specified Subgroup Meta-analysis

Author

Galli, Mattia, primary, Laborante, Renzo, additional, Occhipinti, Giovanni, additional, Zito, Andea, additional, Spadafora, Luigi, additional, Biondi-Zoccai, Giuseppe, additional, Nerla, Roberto, additional, Castriota, Fausto, additional, D'Amario, Domenico, additional, Capodanno, Davide, additional, Jeong, Young-Hoon, additional, Kimura, Takeshi, additional, Mehran, Roxana, additional, and Angiolillo, Dominick J, additional

Published
2023
Full Text
View/download PDF

13. Bivalirudin in acute coronary syndromes

Author

Galli, Mattia, primary, Bernardi, Marco, additional, Ortega-Paz, Luis, additional, Nerla, Roberto, additional, D’Amario, Domenico, additional, Franchi, Francesco, additional, Biondi-Zoccai, Giuseppe, additional, and Angiolillo, Dominick J., additional

Published
2023
Full Text
View/download PDF

14. Valve-in-Valve Implantation Using the ACURATE Neo in Degenerated Aortic Bioprostheses: An International Multicenter Analysis

Author

Holzamer, Andreas, Kim, Won-Keun, Rück, Andreas, Sathananthan, Janarthanan, Keller, Lukas, Cosma, Joseph, Bauer, Timm, Nef, Holger, Amat-Santos, Ignacio J., Brinkert, Miriam, Husser, Oliver, Pellegrini, Costanza, Schofer, Joachim, Nerla, Roberto, Montorfano, Matteo, Giannini, Francesco, Stella, Pieter, Kuwata, Shingo, Hilker, Michael, Castriota, Fausto, Ussia, Gian Paolo, Webb, John G., Nietlispach, Fabian, and Toggweiler, Stefan

Published
2019
Full Text
View/download PDF

17. Chimney Stenting vs BASILICA for Prevention of Acute Coronary Obstruction During Transcatheter Aortic Valve Replacement.

Author

Mangieri, Antonio, Richter, Ines, Gitto, Mauro, Abdelhafez, Ahmed, Bedogni, Francesco, Lanz, Jonas, Montorfano, Matteo, Unbehaun, Axel, Giannini, Francesco, Nerla, Roberto, Taramasso, Maurizio, Ielasi, Alfonso, Rudolph, Tanja, Ferlini, Marco, Ribichini, Flavio, Poletti, Enrico, Latib, Azeem, Colombo, Antonio, Van Mieghem, Nicolas M., and Thiele, Holger

Abstract

Coronary obstruction (CO) is a potentially life-threatening complication of transcatheter aortic valve replacement (TAVR). Chimney stenting or leaflet laceration with transcatheter electrosurgery (Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction [BASILICA]) are 2 techniques developed to prevent CO. The aim of the present study was to compare periprocedural and 1-year outcomes of chimney and BASILICA in TAVR patients at high risk of CO. This multicenter observational registry enrolled consecutive TAVR patients at high risk of CO, undergoing either preventive chimney stenting or BASILICA. Clinical success was defined as successful performance of the chimney or BASILICA technique without clinically relevant ostial CO. The primary endpoint was major adverse cardiovascular events, a composite of death, myocardial infarction, stroke, or unplanned target lesion coronary revascularization at 1 year. A total of 168 patients were included: 71 (42.3%) received chimney stenting, and 97 (57.7%) underwent BASILICA. Patients undergoing BASILICA had higher preprocedural risk of CO, as indicated by lower sinotubular junction height (18.2 ± 4.8 mm vs 14.8 ± 3.4 mm; P < 0.001) and diameter (28.2 ± 4.5 vs 26.8 ± 3.4; P = 0.029). Rates of periprocedural complications were similar between the 2 groups. Clinical success was 97.2% and 96.9% in chimney and BASILICA, respectively (P = 0.92). At 1-year follow-up, the cumulative incidence of major adverse cardiovascular events was 18.7% (95% CI: 11%-30.6%) in the chimney group and 19.9% (95% CI: 12.1%-31.5%) in the BASILICA group (log-rank P = 0.848), whereas chimney was associated with a numerically higher cardiovascular mortality than BASILICA (6.7% vs 1.3%; log-rank P = 0.168). Chimney stenting and BASILICA effectively prevent TAVR-induced acute CO. Both techniques seem to have comparable acceptable periprocedural and 1-year outcomes. [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Uncommon Carotid Artery Stenting Complications: A Series by Images.

Author

Vadalà, Giuseppe, Sucato, Vincenzo, Costa, Francesco, Castriota, Fausto, Nerla, Roberto, Roscitano, Giuseppe, Versace, Antonio Giovanni, Galassi, Alfredo Ruggero, and Micari, Antonio

Subjects
CAROTID artery, CAROTID artery stenosis, CAROTID endarterectomy, RADIAL artery, OLDER patients, STROKE
Abstract

Aims: To describe through emblematic images rare but clinically relevant carotid artery stenting complications that occurred at two high-volume centres for carotid artery stenting (CAS). Background: CAS is an alternative to carotid endarterectomy (CEA) for the treatment of carotid artery stenosis in patients judged to be at high risk for CEA. CAS complications range between 1 and 9% and are higher in older patients complaining of neurological symptoms at the time of presentation. Besides periprocedural or early-after-procedure stroke, which remains the true Achilles' heel of CAS, other dramatic complications might compromise the clinical outcomes of this procedure. Methods: Five infrequent complications, out of more than 1000 CAS performed in the years 2016–2021, have been described. Results: Among CAS complications, acute carotid stent thrombosis, rescue retrieval of a disconnected distal cerebral embolic protection device, plaque prolapse after carotid stenting, cerebral hyperperfusion syndrome (CHS), and radial artery long sheath entrapment requiring surgical intervention were found to account for 0.3% of the total number of procedures performed by operators with high CAS volume. Conclusions: Unusual CAS complications may infrequently occur, even in hands of expert operators. To know how to deal with such complications might help interventionalists to improve CAS performance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Gender Differences in CAS

Author

Borghesi, Marco, Dozza, Luca, Nerla, Roberto, Micari, Antonio, Grattoni, Chiara, Castriota, Fausto, Cremonesi, Alberto, Presbitero, Patrizia, editor, Mehilli, Julinda, editor, and Petronio, Anna Sonia, editor

Published
2017
Full Text
View/download PDF

20. Delayed Coronary Obstruction After Transcatheter Aortic Valve Replacement

Author

Jabbour, Richard J., Tanaka, Akihito, Finkelstein, Ariel, Mack, Michael, Tamburino, Corrado, Van Mieghem, Nicolas, de Backer, Ole, Testa, Luca, Gatto, Pamela, Purita, Paola, Rahhab, Zouhair, Veulemans, Verena, Stundl, Anja, Barbanti, Marco, Nerla, Roberto, Sinning, Jan Malte, Dvir, Danny, Tarantini, Giuseppe, Szerlip, Molly, Scholtz, Werner, Scholtz, Smita, Tchetche, Didier, Castriota, Fausto, Butter, Christian, Søndergaard, Lars, Abdel-Wahab, Mohamed, Sievert, Horst, Alfieri, Ottavio, Webb, John, Rodés-Cabau, Josep, Colombo, Antonio, and Latib, Azeem

Published
2018
Full Text
View/download PDF

26. Cutting balloon to optimize predilation for stent implantation: The COPS randomized trial

Author

Mangieri, Antonio, primary, Nerla, Roberto, additional, Castriota, Fausto, additional, Reimers, Bernhard, additional, Regazzoli, Damiano, additional, Leone, Pier P., additional, Gasparini, Gabriele L., additional, Khokhar, Arif A., additional, Laricchia, Alessandra, additional, Giannini, Francesco, additional, Casale, Fulvio, additional, Bezzeccheri, Andrea, additional, Briguori, Carlo, additional, and Colombo, Antonio, additional

Published
2023
Full Text
View/download PDF

27. Vascular Access in Patients With Peripheral Arterial Disease Undergoing TAVR:The Hostile Registry

Author

Palmerini, Tullio, Saia, Francesco, Kim, Won Keun, Renker, Matthias, Iadanza, Alessandro, Fineschi, Massimo, Bruno, Antonio Giulio, Ghetti, Gabriele, Vanhaverbeke, Maarten, Søndergaard, Lars, De Backer, Ole, Romagnoli, Enrico, Burzotta, Francesco, Trani, Carlo, Adrichem, Rik, Van Mieghem, Nicolas M., Nardi, Elena, Chietera, Francesco, Orzalkiewicz, Mateusz, Tomii, Daijiro, Pilgrim, Thomas, Aranzulla, Tiziana Claudia, Musumeci, Giuseppe, Adam, Matti, Meertens, Max M., Taglieri, Nevio, Marrozzini, Cinzia, Alvarez Covarrubias, Hector Alfonso, Joner, Michael, Nardi, Giulia, Di Muro, Francesca Maria, Di Mario, Carlo, Loretz, Lucca, Toggweiler, Stefan, Gallitto, Enrico, Gargiulo, Mauro, Testa, Luca, Bedogni, Francesco, Berti, Sergio, Ancona, Marco B., Montorfano, Matteo, Leone, Alessandro, Savini, Carlo, Pacini, Davide, Gmeiner, Jonas, Braun, Daniel, Nerla, Roberto, Castriota, Fausto, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Costa, Giuliano, Tamburino, Corrado, Leone, Pier Pasquale, Reimers, Bernhard, Stefanini, Giulio, Sudo, Mitsumasa, Nickenig, Georg, Piva, Tommaso, Scotti, Andrea, Latib, Azeem, Vercellino, Matteo, Porto, Italo, Codner, Pablo, Kornowski, Ran, Bartorelli, Antonio L., Tarantini, Giuseppe, Fraccaro, Chiara, Abdel-Wahab, Mohamed, Grube, Eberhard, Galié, Nazzareno, Stone, Gregg W., Palmerini, Tullio, Saia, Francesco, Kim, Won Keun, Renker, Matthias, Iadanza, Alessandro, Fineschi, Massimo, Bruno, Antonio Giulio, Ghetti, Gabriele, Vanhaverbeke, Maarten, Søndergaard, Lars, De Backer, Ole, Romagnoli, Enrico, Burzotta, Francesco, Trani, Carlo, Adrichem, Rik, Van Mieghem, Nicolas M., Nardi, Elena, Chietera, Francesco, Orzalkiewicz, Mateusz, Tomii, Daijiro, Pilgrim, Thomas, Aranzulla, Tiziana Claudia, Musumeci, Giuseppe, Adam, Matti, Meertens, Max M., Taglieri, Nevio, Marrozzini, Cinzia, Alvarez Covarrubias, Hector Alfonso, Joner, Michael, Nardi, Giulia, Di Muro, Francesca Maria, Di Mario, Carlo, Loretz, Lucca, Toggweiler, Stefan, Gallitto, Enrico, Gargiulo, Mauro, Testa, Luca, Bedogni, Francesco, Berti, Sergio, Ancona, Marco B., Montorfano, Matteo, Leone, Alessandro, Savini, Carlo, Pacini, Davide, Gmeiner, Jonas, Braun, Daniel, Nerla, Roberto, Castriota, Fausto, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Costa, Giuliano, Tamburino, Corrado, Leone, Pier Pasquale, Reimers, Bernhard, Stefanini, Giulio, Sudo, Mitsumasa, Nickenig, Georg, Piva, Tommaso, Scotti, Andrea, Latib, Azeem, Vercellino, Matteo, Porto, Italo, Codner, Pablo, Kornowski, Ran, Bartorelli, Antonio L., Tarantini, Giuseppe, Fraccaro, Chiara, Abdel-Wahab, Mohamed, Grube, Eberhard, Galié, Nazzareno, and Stone, Gregg W.

Abstract

Background: The optimal access route in patients with severe peripheral artery disease (PAD) undergoing transcatheter aortic valve replacement (TAVR) remains undetermined. Objectives: This study sought to compare clinical outcomes with transfemoral access (TFA), transthoracic access (TTA), and nonthoracic transalternative access (TAA) in TAVR patients with severe PAD. Methods: Patients with PAD and hostile femoral access (TFA impossible, or possible only after percutaneous treatment) undergoing TAVR at 28 international centers were included in this registry. The primary endpoint was the propensity-adjusted risk of 30-day major adverse events (MAE) defined as the composite of all-cause mortality, stroke/transient ischemic attack (TIA), or main access site–related Valve Academic Research Consortium 3 major vascular complications. Outcomes were also stratified according to the severity of PAD using a novel risk score (Hostile score). Results: Among the 1,707 patients included in the registry, 518 (30.3%) underwent TAVR with TFA after percutaneous treatment, 642 (37.6%) with TTA, and 547 (32.0%) with TAA (mostly transaxillary). Compared with TTA, both TFA (adjusted HR: 0.58; 95% CI: 0.45-0.75) and TAA (adjusted HR: 0.60; 95% CI: 0.47-0.78) were associated with lower 30-day rates of MAE, driven by fewer access site–related complications. Composite risks at 1 year were also lower with TFA and TAA compared with TTA. TFA compared with TAA was associated with lower 1-year risk of stroke/TIA (adjusted HR: 0.49; 95% CI: 0.24-0.98), a finding confined to patients with low Hostile scores (Pinteraction = 0.049). Conclusions: Among patients with PAD undergoing TAVR, both TFA and TAA were associated with lower 30-day and 1-year rates of MAE compared with TTA, but 1-year stroke/TIA rates were higher with TAA compared with TFA.

Published
2023

30. TCT-137 Contribution of Plaque Composition to the Extent of Plaque Fracture and Dissection Following Drug-Coated Balloon Angioplasty in De Novo Small Vessel Disease: An Interim Report of the TRANSFORM-I Trial

Author

Ninomiya, Kai, primary, Serruys, Patrick, additional, Huang, Jiayue, additional, Masuda, Shinichiro, additional, Ding, Daixin, additional, Doshi, Manish, additional, Tu, Shengxian, additional, Dijkstra, Jouke, additional, Nerla, Roberto, additional, di Mario, Carlo, additional, Testa, Luca, additional, Cortese, Bernardo, additional, Basavarajaiah, Sandeep, additional, Colombo, Antonio, additional, Sharif, Faisal, additional, and Onuma, Yoshinobu, additional

Published
2022
Full Text
View/download PDF

31. Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type

Author

Landes, Uri, primary, Richter, Ilan, additional, Danenberg, Haim, additional, Kornowski, Ran, additional, Sathananthan, Janarthanan, additional, De Backer, Ole, additional, Søndergaard, Lars, additional, Abdel-Wahab, Mohamed, additional, Yoon, Sung-Han, additional, Makkar, Raj R., additional, Thiele, Holger, additional, Kim, Won-Keun, additional, Hamm, Christian, additional, Buzzatti, Nicola, additional, Montorfano, Matteo, additional, Ludwig, Sebastian, additional, Schofer, Niklas, additional, Voigtlaender, Lisa, additional, Guerrero, Mayra, additional, El Sabbagh, Abdallah, additional, Rodés-Cabau, Josep, additional, Mesnier, Jules, additional, Okuno, Taishi, additional, Pilgrim, Thomas, additional, Fiorina, Claudia, additional, Colombo, Antonio, additional, Mangieri, Antonio, additional, Eltchaninoff, Helene, additional, Nombela-Franco, Luis, additional, Van Wiechen, Maarten P.H., additional, Van Mieghem, Nicolas M., additional, Tchétché, Didier, additional, Schoels, Wolfgang H., additional, Kullmer, Matthias, additional, Barbanti, Marco, additional, Tamburino, Corrado, additional, Sinning, Jan-Malte, additional, Al-Kassou, Baravan, additional, Perlman, Gidon Y., additional, Ielasi, Alfonso, additional, Fraccaro, Chiara, additional, Tarantini, Giuseppe, additional, De Marco, Federico, additional, Witberg, Guy, additional, Redwood, Simon R., additional, Lisko, John C., additional, Babaliaros, Vasilis C., additional, Laine, Mika, additional, Nerla, Roberto, additional, Finkelstein, Ariel, additional, Eitan, Amnon, additional, Jaffe, Ronen, additional, Ruile, Philipp, additional, Neumann, Franz J., additional, Piazza, Nicolo, additional, Sievert, Horst, additional, Sievert, Kolja, additional, Russo, Marco, additional, Andreas, Martin, additional, Bunc, Matjaz, additional, Latib, Azeem, additional, Bruoha, Sharon, additional, Godfrey, Rebecca, additional, Hildick-Smith, David, additional, Barbash, Israel, additional, Segev, Amit, additional, Maurovich-Horvat, Pál, additional, Szilveszter, Balint, additional, Spargias, Konstantinos, additional, Aravadinos, Dionisis, additional, Nazif, Tamim M., additional, Leon, Martin B., additional, and Webb, John G., additional

Published
2022
Full Text
View/download PDF

35. Transcatheter Aortic Valve Replacement With Self-Expanding ACURATE neo2

Author

Buono, Andrea, primary, Gorla, Riccardo, additional, Ielasi, Alfonso, additional, Costa, Giuliano, additional, Cozzi, Ottavia, additional, Ancona, Marco, additional, Soriano, Francesco, additional, De Carlo, Marco, additional, Ferrara, Erica, additional, Giannini, Francesco, additional, Massussi, Mauro, additional, Fovino, Luca Nai, additional, Pero, Gaetano, additional, Bettari, Luca, additional, Acerbi, Elena, additional, Messina, Antonio, additional, Sgroi, Carmelo, additional, Pellicano, Mariano, additional, Sun, Jinwei, additional, Gallo, Francesco, additional, Franchina, Antonio Gabriele, additional, Bruno, Francesco, additional, Nerla, Roberto, additional, Saccocci, Matteo, additional, Villa, Emmanuel, additional, D’Ascenzo, Fabrizio, additional, Conrotto, Federico, additional, Cuccia, Claudio, additional, Tarantini, Giuseppe, additional, Fiorina, Claudia, additional, Castriota, Fausto, additional, Poli, Arnaldo, additional, Petronio, Anna Sonia, additional, Oreglia, Jacopo, additional, Montorfano, Matteo, additional, Regazzoli, Damiano, additional, Reimers, Bernhard, additional, Tamburino, Corrado, additional, Tespili, Maurizio, additional, Bedogni, Francesco, additional, Barbanti, Marco, additional, and Maffeo, Diego, additional

Published
2022
Full Text
View/download PDF

39. Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type

Author

Landes, Uri, Richter, Ilan, Danenberg, Haim, Kornowski, Ran, Sathananthan, Janarthanan, De Backer, Ole, Søndergaard, Lars, Abdel-Wahab, Mohamed, Yoon, Sung Han, Makkar, Raj R., Thiele, Holger, Kim, Won Keun, Hamm, Christian, Buzzatti, Nicola, Montorfano, Matteo, Ludwig, Sebastian, Schofer, Niklas, Voigtlaender, Lisa, Guerrero, Mayra, El Sabbagh, Abdallah, Rodés-Cabau, Josep, Mesnier, Jules, Okuno, Taishi, Pilgrim, Thomas, Fiorina, Claudia, Colombo, Antonio, Mangieri, Antonio, Eltchaninoff, Helene, Nombela-Franco, Luis, Van Wiechen, Maarten P.H., Van Mieghem, Nicolas M., Tchétché, Didier, Schoels, Wolfgang H., Kullmer, Matthias, Barbanti, Marco, Tamburino, Corrado, Sinning, Jan Malte, Al-Kassou, Baravan, Perlman, Gidon Y., Ielasi, Alfonso, Fraccaro, Chiara, Tarantini, Giuseppe, De Marco, Federico, Witberg, Guy, Redwood, Simon R., Lisko, John C., Babaliaros, Vasilis C., Laine, Mika, Nerla, Roberto, Finkelstein, Ariel, Eitan, Amnon, Jaffe, Ronen, Ruile, Philipp, Neumann, Franz J., Piazza, Nicolo, Sievert, Horst, Sievert, Kolja, Russo, Marco, Andreas, Martin, Bunc, Matjaz, Latib, Azeem, Bruoha, Sharon, Godfrey, Rebecca, Hildick-Smith, David, Barbash, Israel, Segev, Amit, Maurovich-Horvat, Pál, Szilveszter, Balint, Spargias, Konstantinos, Aravadinos, Dionisis, Nazif, Tamim M., Leon, Martin B., Webb, John G., Landes, Uri, Richter, Ilan, Danenberg, Haim, Kornowski, Ran, Sathananthan, Janarthanan, De Backer, Ole, Søndergaard, Lars, Abdel-Wahab, Mohamed, Yoon, Sung Han, Makkar, Raj R., Thiele, Holger, Kim, Won Keun, Hamm, Christian, Buzzatti, Nicola, Montorfano, Matteo, Ludwig, Sebastian, Schofer, Niklas, Voigtlaender, Lisa, Guerrero, Mayra, El Sabbagh, Abdallah, Rodés-Cabau, Josep, Mesnier, Jules, Okuno, Taishi, Pilgrim, Thomas, Fiorina, Claudia, Colombo, Antonio, Mangieri, Antonio, Eltchaninoff, Helene, Nombela-Franco, Luis, Van Wiechen, Maarten P.H., Van Mieghem, Nicolas M., Tchétché, Didier, Schoels, Wolfgang H., Kullmer, Matthias, Barbanti, Marco, Tamburino, Corrado, Sinning, Jan Malte, Al-Kassou, Baravan, Perlman, Gidon Y., Ielasi, Alfonso, Fraccaro, Chiara, Tarantini, Giuseppe, De Marco, Federico, Witberg, Guy, Redwood, Simon R., Lisko, John C., Babaliaros, Vasilis C., Laine, Mika, Nerla, Roberto, Finkelstein, Ariel, Eitan, Amnon, Jaffe, Ronen, Ruile, Philipp, Neumann, Franz J., Piazza, Nicolo, Sievert, Horst, Sievert, Kolja, Russo, Marco, Andreas, Martin, Bunc, Matjaz, Latib, Azeem, Bruoha, Sharon, Godfrey, Rebecca, Hildick-Smith, David, Barbash, Israel, Segev, Amit, Maurovich-Horvat, Pál, Szilveszter, Balint, Spargias, Konstantinos, Aravadinos, Dionisis, Nazif, Tamim M., Leon, Martin B., and Webb, John G.

Abstract

Background: As transcatheter aortic valve (TAV) replacement is increasingly used in patients with longer life expectancy, a sizable proportion will require redo TAV replacement (TAVR). The unique configuration of balloon-expandable TAV (bTAV) vs a self-expanding TAV (sTAV) potentially affects TAV-in-TAV outcome. Objectives: The purpose of this study was to better inform prosthesis selection, TAV-in-TAV outcomes were assessed according to the type of initial and subsequent TAV. Methods: Patients from the Redo-TAVR registry were analyzed using propensity weighting according to their initial valve type (bTAV [n = 115] vs sTAV [n = 106]) and subsequent valve type (bTAV [n = 130] vs sTAV [n = 91]). Results: Patients with failed bTAVs presented later (vs sTAV) (4.9 ± 2.1 years vs 3.7 ± 2.3 years; P < 0.001), with smaller effective orifice area (1.0 ± 0.7 cm2 vs 1.3 ± 0.8 cm2; P = 0.018) and less frequent dominant regurgitation (16.2% vs 47.3%; P < 0.001). Mortality at 30 days was 2.3% (TAV-in-bTAV) vs 0% (TAV-in-sTAV) (P = 0.499) and 1.7% (bTAV-in-TAV) vs 1.0% (sTAV-in-TAV) (P = 0.612); procedural safety was 72.6% (TAV-in-bTAV) vs 71.2% (TAV-in-sTAV) (P = 0.817) and 73.2% (bTAV-in-TAV) vs 76.5% (sTAV-in-TAV) (P = 0.590). Device success was similar according to initial valve type but higher with subsequent sTAV vs bTAV (77.2% vs 64.3%; P = 0.045), primarily because of lower residual gradients (10.3 mm Hg [8.9-11.7 mm Hg] vs 15.2 mm Hg [13.2-17.1 mm Hg]; P < 0.001). Residual regurgitation (moderate or greater) was similar after bTAV-in-TAV and sTAV-in-TAV (5.7%) and nominally higher after TAV-in-bTAV (9.1%) vs TAV-in-sTAV (4.4%) (P = 0.176). Conclusions: In selected patients, no association was observed between TAV type and redo TAVR safety or mortality, yet subsequent sTAV was associated with higher device success because of lower redo gradients. These findings are preliminary, and more data are needed to guide valve choice for redo TAVR.

Published
2022

41. Gender Differences in CAS

Author

Borghesi, Marco, primary, Dozza, Luca, additional, Nerla, Roberto, additional, Micari, Antonio, additional, Grattoni, Chiara, additional, Castriota, Fausto, additional, and Cremonesi, Alberto, additional

Published
2016
Full Text
View/download PDF

42. Transcatheter Aortic Valve Replacement With Self-Expanding ACURATE neo2: Postprocedural Hemodynamic and Short-Term Clinical Outcomes

Author

Buono, Andrea, Gorla, Riccardo, Ielasi, Alfonso, Costa, Giuliano, Cozzi, Ottavia, Ancona, Marco, Soriano, Francesco, De Carlo, Marco, Ferrara, Erica, Giannini, Francesco, Massussi, Mauro, Fovino, Luca Nai, Pero, Gaetano, Bettari, Luca, Acerbi, Elena, Messina, Antonio, Sgroi, Carmelo, Pellicano, Mariano, Sun, Jinwei, Gallo, Francesco, Franchina, Antonio Gabriele, Bruno, Francesco, Nerla, Roberto, Saccocci, Matteo, Villa, Emmanuel, D'Ascenzo, Fabrizio, Conrotto, Federico, Cuccia, Claudio, Tarantini, Giuseppe, Fiorina, Claudia, Castriota, Fausto, Poli, Arnaldo, Petronio, Anna Sonia, Oreglia, Jacopo, Montorfano, Matteo, Regazzoli, Damiano, Reimers, Bernhard, Tamburino, Corrado, Tespili, Maurizio, Bedogni, Francesco, Barbanti, Marco, and Maffeo, Diego

Subjects
Aortic Valve Insufficiency, Hemodynamics, SE THV, Aortic Valve Stenosis, TAVR, Prosthesis Design, aortic regurgitation, Transcatheter Aortic Valve Replacement, Treatment Outcome, ACURATE neo2, paravalvular leak, Aortic Valve, Heart Valve Prosthesis, self-expanding THV, Humans, Retrospective Studies
Abstract

The first-generation ACURATE neo transcatheter heart valve (THV) (Boston Scientific) was associated with a non-negligible occurrence of moderate or greater paravalvular aortic regurgitation (AR) following transcatheter aortic valve replacement. To overcome this issue, the ACURATE neo2 iteration, which incorporates a taller outer skirt aimed at reducing the occurrence of paravalvular AR, has recently been developed.The aim of this study was to assess the efficacy and safety of the ACURATE neo2 (Boston Scientific) THV in patients with severe aortic valve stenosis.ITAL-neo was an observational, retrospective, multicenter registry enrolling consecutive patients with severe aortic valve stenosis, treated with first- and second-generation ACURATE neo THVs, via transfemoral and trans-subclavian access, in 13 Italian centers. One-to-one propensity score matching was applied to account for baseline characteristics unbalance. The primary endpoint was the occurrence of moderate or greater paravalvular AR on predischarge echocardiographic assessment. Secondary endpoints included postprocedural technical success and 90-day device success and safety.Among 900 patients included in the registry, 220 received the ACURATE neo2 THV, whereas 680 were treated with the first-generation device. A total of 410 patients were compared after 1:1 propensity score matching. The ACURATE neo2 THV was associated with a 3-fold lower frequency of postprocedural moderate or greater paravalvular AR (11.2% vs 3.5%; P 0.001). No other hemodynamic differences were observed. Postprocedural technical success was similar between the 2 cohorts. Fewer adverse events were observed in patients treated with the ACURATE neo2 at 90 days.Transfemoral transcatheter aortic valve replacement using the ACURATE neo2 was associated with a significant lower frequency of moderate or greater paravalvular AR compared with the earlier generation ACURATE neo device, with encouraging short-term safety and efficacy.

Published
2021

47. Severe Valvular Heart Disease and COVID-19: Results from the Multicenter International Valve Disease Registry

Author

Dvir, Danny, primary, Simonato, Matheus, additional, Amat-Santos, Ignacio, additional, Latib, Azeem, additional, Kargoli, Faraj, additional, Nombela-Franco, Luis, additional, Agrifoglio, Marco, additional, Giannini, Francesco, additional, Regazzoli, Damiano, additional, Reimers, Bernhard, additional, Villa, Emmanuel, additional, M. Becerra-Muñoz, Victor, additional, Mennuni, Marco, additional, Rognoni, Andrea, additional, Modine, Thomas, additional, Leroux, Lionel, additional, Estévez-Loureiro, Rodrigo, additional, Nerla, Roberto, additional, Castriota, Fausto, additional, Cerillo, Alfredo, additional, Søndergaard, Lars, additional, Iadanza, Alessandro, additional, Duncan, Alison, additional, Vincent, Flavien, additional, Mancone, Massimo, additional, Birtolo, Lucia, additional, Maestrini, Viviana, additional, Testa, Luca, additional, Wojakowski, Wojtek, additional, Salizzoni, Stefano, additional, Esteves, Vinicius, additional, Mangione, Fernanda, additional, Zukowski, Cleverson, additional, Amabile, Nicolas, additional, Shuvy, Mony, additional, and Stone, Gregg W., additional

Published
2021
Full Text
View/download PDF

48. Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement

Author

Alperi, Alberto, Rodes-Cabau, Josep, Simonato, Matheus, Tchetche, Didier, Charbonnier, Gaetan, Ribeiro, Henrique B., Latib, Azeem, Montorfano, Matteo, Barbanti, Marco, Bleiziffer, Sabine, Redfors, Bjorn, Abdel-Wahab, Mohamed, Allali, Abdelhakim, Bruschi, Giuseppe, Napodano, Massimo, Agrifoglio, Marco, Petronio, Anna Sonia, Giannini, Cristina, Chan, Albert, Kornowski, Ran, Pravda, Nili Schamroth, Adam, Matti, Iadanza, Alessandro, Noble, Stephane, Chatfield, Andrew, Erlebach, Magdalena, Kempfert, Joerg, Ubben, Timm, Wijeysundera, Harindra, Seiffert, Moritz, Pilgrim, Thomas, Kim, Won-Keun, Testa, Luca, Hildick-Smith, David, Nerla, Roberto, Fiorina, Claudia, Brinkmann, Christina, Conzelmann, Lars, Champagnac, Didier, Saia, Francesco, Nissen, Henrik, Amrane, Hafid, Whisenant, Brian, Shamekhi, Jasmin, Sondergaard, Lars, Webb, John G., Dvir, Danny, Alperi, Alberto, Rodes-Cabau, Josep, Simonato, Matheus, Tchetche, Didier, Charbonnier, Gaetan, Ribeiro, Henrique B., Latib, Azeem, Montorfano, Matteo, Barbanti, Marco, Bleiziffer, Sabine, Redfors, Bjorn, Abdel-Wahab, Mohamed, Allali, Abdelhakim, Bruschi, Giuseppe, Napodano, Massimo, Agrifoglio, Marco, Petronio, Anna Sonia, Giannini, Cristina, Chan, Albert, Kornowski, Ran, Pravda, Nili Schamroth, Adam, Matti, Iadanza, Alessandro, Noble, Stephane, Chatfield, Andrew, Erlebach, Magdalena, Kempfert, Joerg, Ubben, Timm, Wijeysundera, Harindra, Seiffert, Moritz, Pilgrim, Thomas, Kim, Won-Keun, Testa, Luca, Hildick-Smith, David, Nerla, Roberto, Fiorina, Claudia, Brinkmann, Christina, Conzelmann, Lars, Champagnac, Didier, Saia, Francesco, Nissen, Henrik, Amrane, Hafid, Whisenant, Brian, Shamekhi, Jasmin, Sondergaard, Lars, Webb, John G., and Dvir, Danny

Abstract

BACKGROUND Permanent pacemaker implantation (PPI) remains one of the main drawbacks of transcatheter aortic valve replacement (TAVR), but scarce data exist on PPI after valve-in-valve (ViV) TAVR, particularly with the use of newer-generation transcatheter heart valves (THVs). OBJECTIVES The goal of this study was to determine the incidence, factors associated with, and clinical impact of PPI in a large series of ViV-TAVR procedures. METHODS Data were obtained from the multicenter VIVID Registry and included the main baseline and procedural characteristics, in-hospital and late (median follow-up: 13 months [interquartile range: 3 to 41 months]) outcomes analyzed according to the need of periprocedural PPI. All THVs except CoreValve, Cribier-Edwards, Sapien, and Sapien XT were considered to be new-generation THVs. RESULTS A total of 1,987 patients without prior PPI undergoing ViV-TAVR from 2007 to 2020 were included. Of these, 128 patients (6.4%) had PPI after TAVR, with a significant decrease in the incidence of PPI with the use of new-generation THVs (4.7% vs. 7.4%; p = 0.017), mainly related to a reduced PPI rate with the Evolut R/Pro versus CoreValve (3.7% vs. 9.0%; p = 0.002). There were no significant differences in PPI rates between newer-generation balloon-and self expanding THVs (6.1% vs. 3.9%; p = 0.18). In the multivariable analysis, older age (odds ratio [OR]: 1.05 for each increase of 1 year; 95% confidence interval [CI]: 1.02 to 1.07; p = 0.001), larger THV size (OR: 1.10; 95% CI: 1.01 to 1.20; p = 0.02), and previous right bundle branch block (OR: 2.04; 95% CI: 1.00 to 4.17; p = 0.05) were associated with an increased risk of PPI. There were no differences in 30-day mortality between the PPI (4.7%) and no-PPI (2.7%) groups (p = 0.19), but PPI patients exhibited a trend toward higher mortality risk at follow-up (hazard ratio: 1.39; 95% CI: 1.02 to 1.91; p = 0.04; p = 0.08 after adjusting for age differences between groups). CONCLUSIONS In a contemporary

Published
2021

49. Mitraclip after failed surgical mitral valve repair—an international multicenter study

Author

Rahhab, Zouhair, Lim, David Scott, Little, Stephen H., Taramasso, Maurizio, Kuwata, Shingo, Saccocci, Matteo, Tamburino, Corrado, Grasso, Carmelo, Frerker, Christian, Wißt, Theresa, Garberich, Ross, Hausleiter, Jörg, Braun, Daniel, Avenatti, Eleonora, Delgado, Victoria, Ussia, Gian Paolo, Castriota, Fausto, Nerla, Roberto, Ince, Hüseyin, Öner, Alper, Estevez-Loureiro, Rodrigo, Latib, Azeem, Regazzoli, Damiano, Piazza, Nicolo, Alosaimi, Hind, de Jaegere, Peter P.T., Bax, Jeroen, Dvir, Danny, Maisano, Francesco, Sorajja, Paul, Reardon, Michael J., Van Mieghem, Nicolas M., Rahhab, Zouhair, Lim, David Scott, Little, Stephen H., Taramasso, Maurizio, Kuwata, Shingo, Saccocci, Matteo, Tamburino, Corrado, Grasso, Carmelo, Frerker, Christian, Wißt, Theresa, Garberich, Ross, Hausleiter, Jörg, Braun, Daniel, Avenatti, Eleonora, Delgado, Victoria, Ussia, Gian Paolo, Castriota, Fausto, Nerla, Roberto, Ince, Hüseyin, Öner, Alper, Estevez-Loureiro, Rodrigo, Latib, Azeem, Regazzoli, Damiano, Piazza, Nicolo, Alosaimi, Hind, de Jaegere, Peter P.T., Bax, Jeroen, Dvir, Danny, Maisano, Francesco, Sorajja, Paul, Reardon, Michael J., and Van Mieghem, Nicolas M.

Abstract

BACKGROUND: Recurrence of mitral regurgitation (MR) after surgical mitral valve repair (SMVR) varies and may require reoperation. Redo mitral valve surgery can be technically challenging and is associated with increased risk of mortality and morbidity. We aimed to assess the feasibility and safety of MitraClip as a treatment strategy after failed SMVR and identify procedure modifications to overcome technical challenges. METHODS AND RESULTS: This international multicenter observational retrospective study collected information for all patients from 16 high-volume hospitals who were treated with MitraClip after failed SMVR from October 29, 2009, until August 1, 2017. Data were anonymously collected. Technical and device success were recorded per modified Mitral Valve Academic Research Consortium criteria. Overall, 104 consecutive patients were included. Median Society of Thoracic Surgeons score was 4.5% and median age was 73 years. At baseline, the majority of patients (82%) were in New York Heart Association class ≥III and MR was moderate or higher in 86% of patients. The cause of MR pre-SMVR was degenerative in 50%, functional in 35%, mixed in 8%, and missing/unknown in 8% of patients. The median time between SMVR and MitraClip was 5.3 (1.9–9.7) years. Technical and device success were 90% and 89%, respectively. Additional/modified imaging was applied in 21% of cases. An MR reduction of ≥1 grade was achieved in 94% of patients and residual MR was moderate or less in 90% of patients. In-hospital all-cause mortality was 2%, and 86% of patients were in New York Heart Association class ≤II. CONCLUSIONS: MitraClip is a safe and less invasive treatment option for patients with recurrent MR after failed SMVR. Additional/ modified imaging may help overcome technical challenges during leaflet grasping.

Published
2021

50. Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement:VIVID Registry

Author

Alperi, Alberto, Rodés-Cabau, Josep, Simonato, Matheus, Tchetche, Didier, Charbonnier, Gaetan, Ribeiro, Henrique B., Latib, Azeem, Montorfano, Matteo, Barbanti, Marco, Bleiziffer, Sabine, Redfors, Björn, Abdel-Wahab, Mohamed, Allali, Abdelhakim, Bruschi, Giuseppe, Napodano, Massimo, Agrifoglio, Marco, Petronio, Anna Sonia, Giannini, Cristina, Chan, Albert, Kornowski, Ran, Pravda, Nili Schamroth, Adam, Matti, Iadanza, Alessandro, Noble, Stephane, Chatfield, Andrew, Erlebach, Magdalena, Kempfert, Jörg, Ubben, Timm, Wijeysundera, Harindra, Seiffert, Moritz, Pilgrim, Thomas, Kim, Won Keun, Testa, Luca, Hildick-Smith, David, Nerla, Roberto, Fiorina, Claudia, Brinkmann, Christina, Conzelmann, Lars, Champagnac, Didier, Saia, Francesco, Nissen, Henrik, Amrane, Hafid, Whisenant, Brian, Shamekhi, Jasmin, Søndergaard, Lars, Webb, John G., Dvir, Danny, Alperi, Alberto, Rodés-Cabau, Josep, Simonato, Matheus, Tchetche, Didier, Charbonnier, Gaetan, Ribeiro, Henrique B., Latib, Azeem, Montorfano, Matteo, Barbanti, Marco, Bleiziffer, Sabine, Redfors, Björn, Abdel-Wahab, Mohamed, Allali, Abdelhakim, Bruschi, Giuseppe, Napodano, Massimo, Agrifoglio, Marco, Petronio, Anna Sonia, Giannini, Cristina, Chan, Albert, Kornowski, Ran, Pravda, Nili Schamroth, Adam, Matti, Iadanza, Alessandro, Noble, Stephane, Chatfield, Andrew, Erlebach, Magdalena, Kempfert, Jörg, Ubben, Timm, Wijeysundera, Harindra, Seiffert, Moritz, Pilgrim, Thomas, Kim, Won Keun, Testa, Luca, Hildick-Smith, David, Nerla, Roberto, Fiorina, Claudia, Brinkmann, Christina, Conzelmann, Lars, Champagnac, Didier, Saia, Francesco, Nissen, Henrik, Amrane, Hafid, Whisenant, Brian, Shamekhi, Jasmin, Søndergaard, Lars, Webb, John G., and Dvir, Danny

Abstract

Background: Permanent pacemaker implantation (PPI) remains one of the main drawbacks of transcatheter aortic valve replacement (TAVR), but scarce data exist on PPI after valve-in-valve (ViV) TAVR, particularly with the use of newer-generation transcatheter heart valves (THVs). Objectives: The goal of this study was to determine the incidence, factors associated with, and clinical impact of PPI in a large series of ViV-TAVR procedures. Methods: Data were obtained from the multicenter VIVID Registry and included the main baseline and procedural characteristics, in-hospital and late (median follow-up: 13 months [interquartile range: 3 to 41 months]) outcomes analyzed according to the need of periprocedural PPI. All THVs except CoreValve, Cribier-Edwards, Sapien, and Sapien XT were considered to be new-generation THVs. Results: A total of 1,987 patients without prior PPI undergoing ViV-TAVR from 2007 to 2020 were included. Of these, 128 patients (6.4%) had PPI after TAVR, with a significant decrease in the incidence of PPI with the use of new-generation THVs (4.7% vs. 7.4%; p = 0.017), mainly related to a reduced PPI rate with the Evolut R/Pro versus CoreValve (3.7% vs. 9.0%; p = 0.002). There were no significant differences in PPI rates between newer-generation balloon- and self-expanding THVs (6.1% vs. 3.9%; p = 0.18). In the multivariable analysis, older age (odds ratio [OR]: 1.05 for each increase of 1 year; 95% confidence interval [CI]: 1.02 to 1.07; p = 0.001), larger THV size (OR: 1.10; 95% CI: 1.01 to 1.20; p = 0.02), and previous right bundle branch block (OR: 2.04; 95% CI: 1.00 to 4.17; p = 0.05) were associated with an increased risk of PPI. There were no differences in 30-day mortality between the PPI (4.7%) and no-PPI (2.7%) groups (p = 0.19), but PPI patients exhibited a trend toward higher mortality risk at follow-up (hazard ratio: 1.39; 95% CI: 1.02 to 1.91; p = 0.04; p = 0.08 after adjusting for age differences between groups). Conclusions: In a cont

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results